NASDAQ · Biotechnology

TuHURA Biosciences, Inc. (HURA) Stock

$1.96 +1.55% NASDAQ: HURA Healthcare

Valuation

MetricValue
Price$1.96
Market Cap$124.82M
P/E Ratio-3.46
P/B Ratio6.47
P/S Ratio0.00
EPS (TTM)$-0.63
52-Week High$3.43
52-Week Low$0.41
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-154.32%
ROA-96.49%
ROCE-138.70%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio0.83

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-23.0M$-15.0M$-8.0M$-18.0M$-32.0M
Net Profit$-23.0M$-15.0M$-8.0M$-22.0M$-30.0M
EPS$-903.03$-324.48$-11.29$-1.21$-0.63
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$6.0M$15.0M$4.0M$20.0M$27.0M
Total Liabilities$7.0M$3.0M$6.0M$5.0M$6.0M
Cash$6.0M$14.0M$4.0M$13.0M$4.0M
Borrowings$1.0M$0$2.0M$0$1.0M

Latest News

TuHURA Biosciences Files New Drug Application for Evaluation of Antibody to Treat Subsets of AML MT Newswires · Jun 15, 2026 TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers PR Newswire · Jun 15, 2026 HURA: Refining TBS-2025 Development Plan Zacks Small Cap Research · May 26, 2026 TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update PR Newswire · May 15, 2026 TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference PR Newswire · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-7.0M$-8.0M$-12.0M$-15.0M$-28.0M
Investing Cash Flow$0$0$-1.0M$-6.0M$-1.0M
Financing Cash Flow$0$0$0$-4.0M$-3.0M
Net Cash Flow$0$9.0M$-11.0M$9.0M$-9.0M
Free Cash Flow$-7.0M$-8.0M$-12.0M$-15.0M$-28.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.03
EV / EBITDA-4.03
FCF Yield-25.11%
Quick Ratio0.18
Interest Coverage-27.83
Return 1Y2.15%
Return 3Y-98.53%
Return 5Y-99.92%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABOSAcumen Pharmaceuticals, Inc. $2.14 +1.90% -1.24 $154.57M 0.00%
AGENAgenus Inc. $7.67 +1.72% 3.66 $319.40M 0.00%
CGTXCognition Therapeutics, Inc. $0.88 -2.04% -4.82 $78.48M 0.00%
INOInovio Pharmaceuticals, Inc. $1.15 +5.50% -1.00 $79.46M 0.00%
IRDOpus Genetics, Inc. $4.65 +4.26% -3.47 $383.93M 0.00%

About TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc. is led by CEO James A. Bianco, employs 19 people, headquartered in US, publicly traded since 2013.

TuHURA Biosciences, Inc. (HURA) stock trades at $1.96 with a market capitalization of $124.82M. The stock is valued at a price-to-earnings (P/E) ratio of -3.46, price-to-book of 6.47, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.41 and $3.43, and currently trades 42.9% below its 52-week high.

On profitability, TuHURA Biosciences, Inc. generates a return on equity (ROE) of -154.32%, return on capital employed of -138.70%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides